Completed PHASE1 INTERVENTIONAL 1-arm NCT05262244

Targeted Fluorescence Imaging in AMD (LEAF)

Targeted Fluorescence Imaging Using Bevacizumab-800CW Within Age-related Macular Degeneration (AMD) Patients to Evaluate the Upregulation of VEGF

Sponsor: University Medical Center Groningen

Conditions Age-Related Macular Degeneration NAMD

Interventions Bevacizumab-IRDye800CW

Updated 7 times since 2022 Last updated: Dec 3, 2024 Started: Oct 28, 2022 Primary completion: Mar 30, 2023 Completion: Mar 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Age-Related Macular Degeneration and NAMD, this trial is completed. The trial is conducted by University Medical Center Groningen and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jan 2025 — Present [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Apr 2023 — Jul 2024 [monthly]

Recruiting PHASE1
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Jun 2022 — Mar 2023 [monthly]

Not Yet Recruiting PHASE1
Apr 2022 — Jun 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Medical Center Groningen

Data source: University Medical Center Groningen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands